NCT07579663尚未招募不适用
Personalized Two-stage Regional Citrate Anticoagulation for CRRT in Patients With Citrate Metabolism Impairment: a Multicenter Randomized Controlled Study
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University0 个研究点目标入组 142 人开始时间: 2026年5月5日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 142
研究概览
简要总结
The purpose of this study is to compare the efficacy and safety of an individualized two-stage calcium supplementation method versus a conventional commercial RCA-CRRT module in RCA-CRRT for patients with citrate metabolism disorders.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A. Aged 18 to 80 years, inclusive, male or female; B. Diagnosed with acute kidney injury or chronic kidney disease stage 5, and assessed by a physician as requiring continuous renal replacement therapy (CRRT); C. Citrate metabolism disorder, including liver failure (acute liver failure, acute-on-chronic liver failure, or decompensated cirrhosis), and/or microcirculation disorder (mean arterial pressure <65 mmHg requiring vasopressor therapy and lactate ≥2 mmol/L); D. The investigator determines that the patient can have a stable vascular access established (the access must be capable of providing a constant and effective blood flow rate >150 ml/min); E. The study participant (subject) and their legal guardian are able to understand the study purpose and provide written informed consent.
排除标准
- •A. Received regional citrate anticoagulation therapy within the previous 72 hours; B. Expected to require additional non-protocol calcium supplementation during CRRT due to disease-related needs; C. Requiring arterial-venous reversal of the extracorporeal circuit during CRRT due to poor flow; D. Requiring concurrent peritoneal dialysis during the trial period; E. Participated in or is currently participating in another clinical trial within 1 month prior to the date of signing the informed consent form; F. Expected survival time less than 72 hours; G. Any other conditions that, in the investigator's judgment, make the patient unsuitable for participation in the clinical trial.
研究者
Ding Feng
Professor
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
相似试验
尚未招募
不适用
Comparison of Citrate and Heparin Anticoagulation During Postdilution HemodiafiltrationRenal FailureNCT07618858University Medical Centre Ljubljana20
尚未招募
不适用
STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary EmbolismPulmonary EmbolismVenous ThromboembolismNCT07603700Nanjing First Hospital, Nanjing Medical University1,300
终止
3 期
Customized Citrate Anticoagulation versus No Anticoagulant in Continuous Venovenous Hemofiltration in Critically ill patients with Acute Kidney InjuryFilter clotting in patients with acute kidney injury requiring continuous venovenous hemofiltrationCVVHregional citrate anticoagulationcustomized citrate-based replacement fluidcitrate accumulationbleedingTCTR20210924001Faculty of Medicine Siriraj Hospital , Mahidol University ,Thailand78
招募中
3 期
Blood thinners after transcatheter implantation of a new heart valve in patients with aortic stenosisAortic stenosis2023-510211-20-00Oslo University Hospital HF360
进行中（未招募）
不适用
Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.NCT07358416Petrovsky National Research Centre of Surgery500